PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value

PAREXEL International Corporation PRXL today announced that the Company has expanded its capabilities to provide biopharmaceutical companies with dedicated support for their commercialization goals. PAREXEL has fully integrated its commercialization services to help clients maximize regional and global market access opportunities. These solutions align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value.